Should a 65-year-old male who had mitral valve repair and a maze procedure with left atrial appendage excision 6 months ago, is on apixaban (Eliquis) and metoprolol, has untreated Crohn’s disease with distal jejunal ulcers, low ferritin possibly due to a large hiatal hernia, and occasional weakness, receive an implantable loop recorder before starting flecainide for atrial fibrillation?

Loop Recorder Before Flecainide: A Reasonable Approach in This Complex Post-Maze Patient

I support obtaining an implantable loop recorder before starting flecainide in this patient, given his structural heart disease from mitral valve repair and maze procedure, the uncertainty about his AF burden, and the significant safety concerns with flecainide in his clinical context.

Critical Safety Concerns with Flecainide in This Patient

This patient has structural heart disease by virtue of his mitral valve repair and maze procedure 6 months ago. The guidelines are unequivocal about flecainide safety: flecainide is associated with increased mortality and ventricular proarrhythmia in patients with structural heart disease, ventricular scar tissue, or left ventricular dysfunction 1. The landmark CAST trial demonstrated increased total mortality and cardiac arrest risk with flecainide in patients with structural heart disease 1.

While the 2016 ACC/AHA/HRS guidelines note flecainide is reasonable for patients without structural heart disease or ischemic heart disease 2, this patient clearly doesn't meet that criterion. His post-surgical cardiac anatomy with valve repair and maze lesions constitutes structural heart disease with potential for ventricular scar tissue.

The Maze Procedure Context Changes Everything

The maze procedure was specifically designed to eliminate AF, and studies show 78-81% freedom from AF at 5 years post-maze with mitral valve surgery 3, 4. The fact that he was found in AF on one visit 6 months post-operatively raises important questions:

• Is this recurrent persistent AF or rare paroxysmal episodes? The maze procedure's success depends partly on time for lesion maturation
• What is his actual AF burden? One documented episode doesn't define the pattern
• Is the AF causing his weakness, or is it the anemia from jejunal ulcers and hiatal hernia bleeding?

The patient's symptoms of weakness are more likely related to his falling ferritin from GI blood loss (jejunal ulcers from Crohn's disease and large hiatal hernia) rather than AF episodes. Treating him empirically with a potentially dangerous antiarrhythmic without knowing his true AF burden is questionable risk-benefit.

Why the Loop Recorder Makes Clinical Sense

Quantifying AF burden before committing to long-term antiarrhythmic therapy is rational medicine, especially when:

1. The drug carries significant mortality risk in his population 1
2. He's already anticoagulated appropriately with apixaban (which is safe post-mitral valve repair 5)
3. His rate is controlled on metoprolol
4. The maze procedure may still be working - he may have minimal AF burden
5. His symptoms may be from anemia, not AF

A 2-4 week external monitor or implantable loop recorder would definitively answer whether he has frequent AF episodes warranting the risks of flecainide, or whether he has rare, brief episodes that don't justify adding a Class IC agent with his structural heart disease.

Alternative Management Strategy

If rhythm control is truly needed based on documented frequent AF:

• Amiodarone would be safer in this structural heart disease patient, though it has long-term toxicity concerns 1
• Dofetilide is another option but requires inpatient initiation with QT monitoring 6
• Rate control optimization with metoprolol dose adjustment may be sufficient if AF burden is low
• Consider EP consultation for potential redo ablation if AF is frequent and symptomatic

Address the Real Problems First

Before escalating antiarrhythmic therapy:

1. Treat the Crohn's disease - untreated inflammatory bowel disease with active ulcers needs therapy 7, 8
2. Evaluate the hiatal hernia - large hernias can trigger AF 9 and cause bleeding
3. Correct the anemia - falling ferritin explains weakness better than paroxysmal AF
4. Optimize PPI therapy - he's already on this, but ensure adequate dosing
5. Monitor rhythm objectively - loop recorder or extended Holter

The Bottom Line

Flecainide carries Class I contraindication-level risk in patients with structural heart disease and heart failure 1. While this patient may not have overt heart failure, his post-surgical cardiac anatomy with maze lesions and valve repair constitutes structural heart disease. Starting flecainide without knowing his AF burden—when he's already adequately anticoagulated and rate-controlled—exposes him to proarrhythmic risk that may be entirely unnecessary.

The loop recorder provides objective data to guide therapy rather than treating based on a single clinic visit finding. This is particularly important given that his weakness is more plausibly explained by anemia from GI bleeding than by AF episodes.

Common Pitfalls to Avoid

• Don't assume one documented AF episode means frequent recurrence - post-maze patients can have isolated episodes
• Don't ignore the structural heart disease - valve surgery and maze lesions count as structural disease for flecainide contraindications
• Don't overlook the obvious cause of weakness - falling ferritin from GI bleeding is the likely culprit
• Don't start Class IC agents without documenting AF burden when safer alternatives exist